comparemela.com

Latest Breaking News On - Datta meghe institute - Page 6 : comparemela.com

NEET Result 2021 Live: Neet nta nic in Exam Scorecards Via Email; Answer Key Soon

NEET Result 2021 Live: Neet nta nic in Exam Scorecards Via Email; Answer Key Soon
ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.

Study backs Ayurvedic drug Ayush 64 in for treatment of mild to moderate Covid-19 infection

Industry > Industry monitor > Healthcare 29 April 2021 Ayush 64, a poly-herbal preparation originally developed by the Central Council for Research in Ayurvedic Sciences (CCRAS) for the treatment of Malaria, in the year 1980 and now repurposed for the treatment Covid-19, has been found to be useful in the treatment of asymptomatic, mild and moderate Covid-19 infection as an adjunct to standard care. Ministry of Ayush and the Council of Scientific and Industrial Research (CSIR) recently collaborated for robust multi-centre clinical trials to evaluate the safety and efficacy of Ayush 64 in the management of mild to moderate Covid-19 patients. Clinical trials were conducted at KGMU, Lucknow; DMIMS, Wardha and BMC Covid Centre, Mumbai, involving 70 participants in each arm. Dr Chopra said Ayush 64 as an adjunct to standard of care (SoC) showed significant improvement and thus lesser period of hospitalisation compared to the only SoC procedure, Dr Arvind Chopra, director, Centre for R

All about AYUSH-64, polyherbal drug found useful in treating mild to moderate COVID cases

All about AYUSH-64, polyherbal drug found useful in treating mild to moderate COVID cases AYUSH-64 can be useful for the treatment of asymptomatic, mild and moderate COVID-19 infection cases, the Ministry of AYUSH said. Share Updated: May 3, 2021, 08:08 PM IST AYUSH-64, a drug developed for curing malaria in 1980, can be useful for the treatment of asymptomatic, mild and moderate COVID-19 infection cases, the Ministry of AYUSH said on Thursday. Central Council for Research in Ayurvedic Sciences (CCRAS) recently concluded clinical trials of the drug focusing on the management of asymptomatic, mild to moderate COVID-19 in collaboration with the Council of Scientific and Industrial Research (CSIR) and other research organizations and medical colleges across the country.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.